M&A
AbbVie to Acquire Apogee Therapeutics for $10.9B
June 9, 2026
Biotech
M&A
Key Facts
Signal Type
M&A
Industry
Biotech
Companies
AbbVie, Apogee Therapeutics, GSK, Nuvalent, Boston Scientific
Date
June 9, 2026
AbbVie announced a $10.9 billion cash acquisition of Apogee Therapeutics on June 22, 2026. The deal aims to strengthen AbbVie's immunology pipeline as reported by Reuters.
Directly impacted parties include Apogee's investors and employees, AbbVie's R&D teams, and competing firms like GSK and Nuvalent mentioned in the article. The acquisition will likely trigger organizational restructuring and portfolio realignments.
Monitor AbbVie's integration timeline and any pipeline prioritization shifts. The article notes similar recent deals by GSK ($10.6B for Nuvalent) and Boston Scientific ($14.5B for Penumbra), suggesting sustained M&A momentum.
Source:
Global Banking & Finance ReviewGet biotech signals in your CRM
FDA approvals and rejections, clinical trial results, pharma M&A, drug recalls, and funding rounds.
